Butorphanol Alleviates Hypoxia/Reoxygenation-Induced Myocardial Injury by Activating Wnt/β-Catenin Signal Pathway
Shi-Rui Hao1, Zi-Feng Xie1, Jia-Xin Li2
1Department of Anesthesiology, First Hospital Affiliated of Jinzhou Medical University, Jinzhou, Liaoning, China.
Abstract:
Ischemic heart disease remains a global health problem with high morbidity and mortality. Butorphanol, as a novel opioid, has been discovered with its cardioprotective properties. The purpose of this study was to explore that butorphanol can alleviate hypoxia/reoxygenation (H/R)-induced myocardial injury by activating the Wnt/β-catenin signal pathway. In this study, Cell Counting Kit-8 (CCK-8), lactate dehydrogenase (LDH) kit, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, and Western blotting experiments were performed to observe butorphanol cardioprotective function and expression of Wnt signaling pathway proteins. For the main result, anti-apoptotic effect and higher expression of Wnt signaling pathway proteins were observed with the increasing concentrations of butorphanol. Compared with the H/R group, higher cellular viability, lower LDH release, and smaller apoptotic cell population were found in the butorphanol group. In addition, expression levels of apoptosis-related protein Bax and Cleaved Caspase-3 decreased, and increased expression of Bcl-2 were observed. Conversely, the protective effects of butorphanol were attenuated in the XAV939 group. In summary, butorphanol attenuates hypoxia/reoxygenation-induced myocardial injury by activating the Wnt/β-catenin signal pathway. Our work provides a theoretical basis for butorphanol's myocardial protective function.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myocarditis III: Medical Management
Canonical Wnt Signaling Pathway
Adrenergic Antagonists: ɑ and β-Receptor Blockers


